Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management

E Sechi, L Cacciaguerra, JJ Chen, S Mariotto… - Frontiers in …, 2022 - frontiersin.org
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is the
most recently defined inflammatory demyelinating disease of the central nervous system …

[HTML][HTML] Serum and cerebrospinal fluid biomarkers in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disease

A Dinoto, E Sechi, EP Flanagan, S Ferrari… - Frontiers in …, 2022 - frontiersin.org
The term neuromyelitis optica spectrum disorder (NMOSD) describes a group of clinical-MRI
syndromes characterized by longitudinally extensive transverse myelitis, optic neuritis …

Complement activation is a prominent feature of MOGAD

CW Keller, JA Lopez, EM Wendel… - Annals of …, 2021 - Wiley Online Library
Myelin oligodendrocyte glycoprotein (MOG)‐antibody (Ab)–associated diseases (MOGADs)
account for a substantial proportion of pediatric and adult patients who present with acquired …

Dissection of complement and Fc-receptor-mediated pathomechanisms of autoantibodies to myelin oligodendrocyte glycoprotein

S Mader, S Ho, HK Wong, S Baier… - Proceedings of the …, 2023 - National Acad Sciences
Autoantibodies against myelin oligodendrocyte glycoprotein (MOG) have recently been
established to define a new disease entity, MOG-antibody-associated disease (MOGAD) …

[HTML][HTML] Pitfalls in complement analysis: A systematic literature review of assessing complement activation

RJ Brandwijk, MAHM Michels, M van Rossum… - Frontiers in …, 2022 - frontiersin.org
Background The complement system is an essential component of our innate defense and
plays a vital role in the pathogenesis of many diseases. Assessment of complement …

Neuromyelitis optica spectrum disorder: from basic research to clinical perspectives

TL Huang, JK Wang, PY Chang, YR Hsu… - International Journal of …, 2022 - mdpi.com
Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disease of the central
nervous system characterized by relapses and autoimmunity caused by antibodies against …

Plasma complement 3 and complement 4 are promising biomarkers for distinguishing NMOSD from MOGAD and are associated with the blood-brain-barrier …

L Lin, Y Wu, H Hang, J Lu, Y Ding - Frontiers in Immunology, 2022 - frontiersin.org
Background and Objective Neuromyelitis optica spectrum disorders (NMOSD) and myelin
oligodendrocyte glycoprotein antibody (MOG-IgG) associated disease (MOGAD) are …

Pathomechanisms in demyelination and astrocytopathy: autoantibodies to AQP4, MOG, GFAP, GRP78 and beyond

S Mader, T Kümpfel, E Meinl - Current Opinion in Neurology, 2022 - journals.lww.com
Pathomechanisms in demyelination and astrocytopathy: autoant... : Current Opinion in
Neurology Pathomechanisms in demyelination and astrocytopathy: autoantibodies to AQP4 …

Genetics behind Cerebral Disease with Ocular Comorbidity: Finding Parallels between the Brain and Eye Molecular Pathology

KJ Chang, HY Wu, AA Yarmishyn, CY Li… - International Journal of …, 2022 - mdpi.com
Cerebral visual impairments (CVIs) is an umbrella term that categorizes miscellaneous
visual defects with parallel genetic brain disorders. While the manifestations of CVIs are …

Neuromyelitis optica spectrum disorders: Clinical perspectives, molecular mechanisms, and treatments

S Thangaleela, BS Sivamaruthi, A Radha, P Kesika… - Applied Sciences, 2023 - mdpi.com
Neuromyelitis optica (NMO) is a rare autoimmune inflammatory disorder affecting the central
nervous system (CNS), specifically the optic nerve and the spinal cord, with severe clinical …